title: Effects of intracavernous injection of P2X3 and NK1 receptor antagonists on erectile dysfunction induced by spinal cord transection in rats.
abstract: This study aimed to explore the effects of intracavernous injection (ICI) of P2X3 and NK1 receptor antagonists on erectile dysfunction (ED) induced by spinal cord transection in rats. Sixty male Sprague-Dawley (SD) rats were randomly divided into the following three groups (20 rats each group): sham operation group (C group), thoracic spinal cord transection group (T group) and sacral spinal cord transection group (S group). An ED model was established through complete transection of the thoracic or sacral spinal cord. Intracavernous pressure (ICP) with and without injection of P2X3 (Suramin) or NK1 (GR82334) receptor antagonists was recorded 3 weeks after surgery. Immunohistochemistry was employed to detect the expression of P2X3 and NK1 receptors in the dorsal root ganglion (DRG) and smooth muscle of corpus cavernosum. Data were processed with SPSS 17.0. ICI with Suramin (0.1, 0.3 and 1 mm) or GR82334 (0.1, 0.3 and 1 mm) increased ICP dose dependently in the T and S groups. The expression of P2X3 and NK1 receptors in DRG and smooth muscle of corpus cavernosum was up-regulated in the T and S groups. It is concluded that ICI of P2X3 and NK1 receptor antagonists may improve the recovery of erectile function in a rat model with ED after spinal cord transection.
authors.affiliation: Family Planning Research Institute, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors.forename: C-L
authors.initials: CL
authors.lastname: Li
authors.forename: X-L
authors.initials: XL
authors.lastname: Yang
authors.forename: J-J
authors.initials: JJ
authors.lastname: Wang
authors.forename: G-H
authors.initials: GH
authors.lastname: Du
authors.forename: W-M
authors.initials: WM
authors.lastname: Yang
authors.forename: H-P
authors.initials: HP
authors.lastname: Zhang
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D007172:Erectile Dysfunction / Q000209:etiology*; D005727:Ganglia, Spinal / Q000378:metabolism; D007150:Immunohistochemistry; D007267:Injections; D008297:Male; D064729:Neurokinin-1 Receptor Antagonists / Q000494:pharmacology*; D010410:Penile Erection / Q000187:drug effects*; D010413:Penis / Q000187:drug effects* / Q000378:metabolism; D010803:Physalaemin / Q000031:analogs & derivatives* / Q000494:pharmacology; D058920:Purinergic P2X Receptor Antagonists / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000378:metabolism; D058477:Receptors, Purinergic P2X3 / Q000378:metabolism; D013119:Spinal Cord Injuries / Q000150:complications*; D013498:Suramin / Q000494:pharmacology*
chemical_list: D064729:Neurokinin-1 Receptor Antagonists; D058920:Purinergic P2X Receptor Antagonists; D018040:Receptors, Neurokinin-1; D058477:Receptors, Purinergic P2X3; C079014:GR 82334; D010803:Physalaemin; D013498:Suramin
keywords: Erectile dysfunction; NK1 receptor; P2X3 receptor; spinal cord transection